|Day Low/High||5.71 / 5.88|
|52 Wk Low/High||2.80 / 9.49|
Additional formularies expand unrestricted access to Auryxia to approximately 85 percent of phosphate binder patients across Medicare Part D and commercial insurance providers
Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Keryx Biopharmaceuticals Inc. saw new options become available this week, for the February 2017 expiration.
Majority of patients when started on Auryxia achieved target serum phosphorus levels within six months of treatment
Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading today, for the January 2019 expiration.
Auryxia is now available for prescription in the U.S.
First presentation of data at a medical conference from pivotal Phase 3 study evaluating ferric citrate as a treatment for iron deficiency anemia in adults with stage 3-5 chronic kidney disease
Shares of Omeros fell almost 10% after analysts' downgraded the biotech.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
Glancy Prongay & Murray LLP ("GPM") reminds investors of the October 3, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired...
In trading on Thursday, shares of Keryx Biopharmaceuticals Inc. crossed above their 200 day moving average of $4.99, changing hands as high as $5.05 per share.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Keryx Biopharmaceuticals, Inc.